Thanks for your interest in our recent AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording.
Initiating antibody discovery with broad diversity of in vivo models increases the probability of successfully identifying therapeutic antibodies against challenging targets. Alloy Therapeutics has developed novel transgenic animal strains for fully human antibody discovery, including strains with Lambda light chains to increase structural diversity and Hyperimmune strains to increase the number of antigen-specific B-cells and enhanced IgG class switching.
Initiating antibody discovery with broad diversity of in vivo models increases the probability of successfully identifying therapeutic antibodies against challenging targets. Alloy Therapeutics has developed novel transgenic animal strains for fully human antibody discovery, including strains with Lambda light chains to increase structural diversity and Hyperimmune strains to increase the number of antigen-specific B-cells and enhanced IgG class switching.
Senior Director, Antibody Technology
To access this content, fill out the form below.
Modalities
Ecosystem
Company
Insights
© 2025 Alloy Therapeutics, Inc. All Rights Reserved.
